馮清州 杜 娟 高偉良 劉 晅
1.深圳市第七人民醫(yī)院ICU,廣東深圳518081;2.暨南大學(xué)第二臨床醫(yī)學(xué)院呼吸內(nèi)科,廣東深圳518081
PI3K信號通路在LPS誘導(dǎo)RAW264.7細胞表達sTREM-1中的作用
馮清州1杜 娟1高偉良2劉 晅1
1.深圳市第七人民醫(yī)院ICU,廣東深圳518081;2.暨南大學(xué)第二臨床醫(yī)學(xué)院呼吸內(nèi)科,廣東深圳518081
目的探討磷脂酰肌醇3-激酶(PI3K)信號通路在脂多糖(LPS)誘導(dǎo)RAW264.7細胞表達可溶性髓樣細胞觸發(fā)受體-1(sTREM-1)中的作用。方法培養(yǎng)小鼠巨噬細胞株RAW264.7,采用相同濃度的LPS在不同時間誘導(dǎo)RAW264.7細胞,應(yīng)用Western blot法分別檢測PI3K蛋白表達水平,RT-PCR法檢測PI3K mRNA表達水平,酶聯(lián)免疫吸附(ELISA)法檢測細胞培養(yǎng)血清中sTREM-1表達水平。用不同濃度PI3K特異性抑制劑LY294002處理細胞,觀察上述指標變化。結(jié)果LPS可時間依賴性地誘導(dǎo)RAW264.7細胞PI3K蛋白、PI3K mRNA的表達;LY294002可濃度依賴性地抑制PI3K蛋白、PI3K mRNA的表達;LY294002阻斷PI3K信號轉(zhuǎn)導(dǎo)通路后,LPS對sTREM-1表達的誘導(dǎo)作用受到顯著抑制,并且具有劑量依賴性。結(jié)論LPS通過PI3K信號通路誘導(dǎo)RAW264.7細胞表達sTREM-1。
磷脂酰肌醇3-激酶;脂多糖;可溶性髓樣細胞觸發(fā)受體-1
可溶性髓樣細胞觸發(fā)受體-1(soluble triggering receptor expressed on myeloid cell-1,sTREM-1)可與下游細胞因子形成一個正反饋的自分泌調(diào)節(jié)回路,促使炎性反應(yīng)增強、放大,影響膿毒癥的發(fā)生發(fā)展[1-2]。sTREM-1是膿毒癥發(fā)病中的早期關(guān)鍵炎癥介質(zhì),但其被誘導(dǎo)表達的信號轉(zhuǎn)導(dǎo)機制尚不十分清楚。研究表明,磷酯酰肌醇3-激酶(phosphoinositide 3-kinase,PI3K)在信號通路被激活時可作為第二信使結(jié)合并激活多種細胞內(nèi)靶蛋白,組成一個信號級聯(lián)系統(tǒng),在炎癥的發(fā)生及發(fā)展過程中發(fā)揮關(guān)鍵的調(diào)控作用,PI3K信號通路為有效干預(yù)炎癥相關(guān)疾病進程的關(guān)鍵靶點[3-4]。在膿毒癥發(fā)病的過程中,PI3K信號轉(zhuǎn)導(dǎo)通路可能影響sTREM-1的表達,本研究對此作出探討,現(xiàn)報道如下。
1.1 試驗材料
小鼠巨噬細胞株RAW264.7細胞(美國ATCC細胞庫);脂多糖(lipopolysaccharide,LPS)(Sigma公司);胰蛋白酶(Sigma公司);DMEM培養(yǎng)基(Gibcol BRL公司);P13K特異性抑制劑LY294002(Promega公司);PI3K的基因引物(上海生工生物科技有限公司);RTPCR試劑盒(日本TaKaRa公司);兔抗鼠PI3K單克隆抗體、羊抗兔IgG單克隆抗體(Santa Cruz公司);小鼠sTREM-1 ELISA試劑盒(深圳晶美公司)。
1.2 試驗方法
1.2.1 試驗分組在37℃、5%CO2恒溫培養(yǎng)箱中,常規(guī)培養(yǎng)小鼠巨噬細胞株RAW264.7,培養(yǎng)基選用DMEM培養(yǎng)液,每48小時更換1次。細胞鋪滿瓶底時傳代,調(diào)整細胞密度為1×106個/ml,接種于6孔板,無血清培養(yǎng)基培養(yǎng),72 h后隨機分組培養(yǎng):①LPS組:加入終濃度為100 mg/ml的LPS培養(yǎng),在加入LPS后1、6、12、24、48 h等不同時間點收集細胞;②LY294002+LPS組:加入不同終濃度為5、10、20 μmol/L的LY294002液預(yù)處理細胞1 h后,加入100 mg/ml LPS刺激1 h后收集細胞。
1.2.2 PI3K蛋白表達檢測采用Western blot法檢測PI3K蛋白表達,收集細胞,經(jīng)PBS洗滌2次,加入裂解液充分裂解,裂解產(chǎn)物12 000 r/min離心20 min,收集上清。使用二辛可酸法(bicinchoninic acid,BCA)測定總蛋白量。每份樣品取50 μg蛋白,加入SDS-Loading Buffer混勻,經(jīng)SDS-聚丙烯酰胺凝膠垂直凝膠電泳300 mA電轉(zhuǎn)移至聚偏二氟乙烯膜。5%脫脂奶粉室溫封2 h,TBS洗膜后分別加PI3K抗體4℃孵育過夜,1∶2500辣根過氧化物酶-羊抗兔IgG單克隆抗體作為二抗孵育PVDF膜,室溫孵育2 h,免疫印跡化學(xué)發(fā)光(ECL)試劑曝光。用抗體剝脫液剝脫抗體后,按同樣的方法與抗β-actin抗體孵育。Quantity One軟件分析蛋白條帶。目的蛋白定量采用灰度比值PI3K/β-actin計算。PI3K相對表達量=PI3K Ct值倒數(shù)/GADPH Ct值倒數(shù)。
1.2.3 PI3K mRNA檢測采用RT-PCR法檢測PI3K mRNA的表達,PI3K的基因引物序列由Primer 5.0軟件自行設(shè)計,上游序列:5′-CC AAG AGC GGT ACA GCA AAG AAT-3′,下游序列:5′-TC GCC GTC CAC CAC TAC AGA-3′,擴增產(chǎn)物長度500 bp。內(nèi)參β-actin的上游引物序列為:5′-GC CTC GCT GTC CAC CTT CCA-3′,下游引物序列為:5′-CA CCT TCA CCG TTC CAG TTT-3′,擴增產(chǎn)物長度為259 bp。收集細胞后用Trizol試劑提取細胞總RNA;按逆轉(zhuǎn)錄試劑盒說明書逆轉(zhuǎn)錄合成cDNA,再利用引物對目的基因進行擴增,擴增后產(chǎn)物于1.5%的瓊脂糖凝膠中電泳,電泳結(jié)束后在凝膠成像系統(tǒng)中進行分析,對各條帶的積分光密度進行測定,然后同內(nèi)參β-actin的光密度積分值進行對比,得出PI3K mRNA表達的相對水平。
1.2.4 sTREM-1表達的影響用ELISA法檢測細胞培養(yǎng)上清液中sTREM-1含量,具體操作遵照說明書進行。
1.3 統(tǒng)計學(xué)方法
采用SPSS 13.0統(tǒng)計學(xué)軟件分析處理,計量資料數(shù)據(jù)采用均數(shù)±標準差(x±s)表示,采用單因素方差分析,以P<0.05為差異有統(tǒng)計學(xué)意義。
2.1 LPS對PI3K蛋白表達的影響
100 mg/ml LPS作用1、6、12、24 h后,PI3K蛋白表達不斷增高,24~48 h PI3K蛋白表達降低(圖1)。
圖1 LPS對PI3K蛋白表達的影響
2.2 LPS對PI3K mRNA表達的影響
100 mg/ml LPS作用1、6、12、24 h后,PI3K mRNA表達不斷增高,24~48 h PI3K mRNA表達降低(圖2)。
圖2 LPS對PI3K mRNA表達的影響
2.3 LY294002對PI3K mRNA表達的影響
LY294002可抑制PI3KmRNA表達,隨著LY294002濃度的增高,抑制作用更加明顯,呈濃度依賴性(圖3)。
圖3 LY294002對PI3K mRNA表達的影響
2.4 LPS對sTREM-1表達水平的影響
隨著LPS(100 mg/ml)作用時間的延長,sTREM-1表達水平呈時間依賴性上升(圖4)。
圖4 LPS對sTREM-1表達水平的影響
2.5 LY294002對sTREM-1表達的影響
LY294002可抑制sTREM-1表達,隨著LY294002濃度的增高,抑制作用更加明顯,呈濃度依賴性(圖5)。
圖5 LY294002對sTREM-1表達的影響與0 μmol/L比較,*P<0.05,**P<0.01
膿毒癥的發(fā)病機制非常復(fù)雜。研究表明,感染致使機體炎癥細胞活化并產(chǎn)生多種促炎因子[5-6],這些因子又可引起更多炎癥細胞的激活,兩者互為因果,形成炎癥級聯(lián)反應(yīng),并且這種級聯(lián)反應(yīng)逐級放大,最終導(dǎo)致膿毒癥的發(fā)生和發(fā)展。因此,適時合理地干預(yù)炎性反應(yīng)的始動環(huán)節(jié),是治療膿毒癥的重要目標。
sTREM-1可選擇性地表達在中性粒細胞和成熟單核、巨噬細胞上,能誘導(dǎo)這些細胞分泌TNF-α、IL-1β、干擾素γ等促炎細胞因子[6-7];sTREM-1還可進一步作用于炎性反應(yīng),促進炎癥因子的釋放,還可正反饋促進TREM-1表達的上調(diào),從而引起炎性反應(yīng)的增強、放大,導(dǎo)致過度的炎性反應(yīng)[8-9],因此,sTREM-1作為一種重要的促炎癥細胞因子,是導(dǎo)致膿毒癥發(fā)生發(fā)展的關(guān)鍵啟動因子,但是關(guān)于膿毒癥時調(diào)控TREM-1表達的機制尚未完全闡明。
PI3K家族是一類同時具有脂質(zhì)與蛋白激酶活性的,可特異性催化磷脂酰肌醇及其衍生物肌醇環(huán)3-位羥基磷酸化,產(chǎn)生具有第二信使作用的肌醇脂物質(zhì)的激酶,PI3K是許多細胞活動、分子信號轉(zhuǎn)導(dǎo)的關(guān)鍵通路[10-12],多種刺激均可導(dǎo)致PI3K活化,通過影響基因的轉(zhuǎn)錄和調(diào)控,調(diào)節(jié)細胞的生物學(xué)行為。
近年研究發(fā)現(xiàn),PI3K信號通路在炎癥的發(fā)生及發(fā)展過程中發(fā)揮關(guān)鍵調(diào)控作用[4,13-14]。在卵清蛋白誘發(fā)的小鼠支氣管哮喘模型中,PI3K能夠減少嗜酸粒細胞的數(shù)目,緩解嗜酸粒細胞增多癥;而PI3K-/-小鼠經(jīng)卵清蛋白誘發(fā)處理后,其導(dǎo)致的嗜酸性氣道炎癥與氣道重構(gòu)較對照組顯著降低,支氣管肺泡灌洗液中嗜酸粒細胞數(shù)目大幅度減少。PI3K亦對肥大細胞功能具有調(diào)節(jié)作用,實驗研究發(fā)現(xiàn),應(yīng)用LY294002及渥曼青霉素等PI3K抑制劑,可減少肥大細胞的脫顆粒[15]。
PI3K信號通路的激活與膿毒癥的發(fā)病亦密切相關(guān)。Yum等[16]研究發(fā)現(xiàn),在注射內(nèi)毒素誘發(fā)的膿毒癥模型中,阻斷PI3K可顯著減少急性肺損傷與水腫的發(fā)生,降低炎癥介質(zhì)濃度與中性粒細胞募集。Martin等[17]利用了盲腸結(jié)扎與穿孔模型,采用多種方式抑制PI3K,結(jié)果顯示其均可保護模型小鼠免受盲腸結(jié)扎與穿孔導(dǎo)致的死亡、肝肺損傷、心血管損傷與凝血功能障礙。而在急性或慢性胰腺炎模型中,PI3K抑制劑可增加實驗組動物存活率,降低疾病嚴重程度,減少組織損傷。因此,阻斷PI3K信號傳導(dǎo)通路可減輕炎癥,達到治療目的。
有學(xué)者發(fā)現(xiàn)PI3K和p38MAPK信號通路通過調(diào)控Ca2+從而參與TREM-1信號傳導(dǎo),PI3K通路的活化可增強sTREM-1的表達,而抑制PI3K活化可抑制sTREM-1的表達[18-20]。而本研究亦發(fā)現(xiàn),LPS誘導(dǎo)RAW264.7細胞后PI3K mRNA表達增高,且呈時間依賴性,同時觀察到sTREM-1表達增高,表明PI3K信號通路可能介導(dǎo)sTREM-1的表達。為明確PI3K信號通路在膿毒癥中對sTREM-1的介導(dǎo)作用,本研究采用PI3K特異性抑制劑LY294002抑制PI3K的活化,結(jié)果顯示在抑制PI3K mRNA表達的同時,對sTREM-1的表達具有拮抗作用,并且具有劑量依賴性??梢姡琍I3K信號通路在LPS誘導(dǎo)RAW264.7細胞表達sTREM-1中可能起到關(guān)鍵作用,PI3K抑制劑可能有助于減輕膿毒癥炎性反應(yīng),這為治療膿毒癥提供了一個新的思路。
[1]Adly AA,Ismail EA,Andrawes NG,et al.Circulating soluble triggering receptor expressed on myeloid cells-1(sTREM-1)as diagnostic and prognostic marker in neonatal sepsis[J]. Cytokine,2014,65(2):184-191.
[2]Ye W,Hu Y,Zhang R,et al.Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in lower respiratorytractinfections:ameta-analysis[J].Respirology,2014,19(4):501-507.
[3]Ebner B,Lange SA,Hollenbach D,et al.In situ postconditioning with neuregulin-1β is mediated by a PI3K/Aktdependent pathway[J].Can J Cardiol,2015,31(1):76-83.
[4]Hawkins PT,Stephens LR,So L,et al.PI3K signalling in B-and T-lymphocytes:new developments and therapeutic advances[J].Biochem J,2012,442(3):465-481.
[5]Bihari D,Prakash S,Bersten A.Low-dose vasopressin in addition to noradrenaline may lead to faster resolution of organ failure in patients with severe sepsis/septic shock[J]. Anaesth Intensive Care,2014,42(5):671-674.
[6]Koch L,Bosk A,Sasse M,et al.Managing neonatal severe sepsis in Germany:a preliminary survey of current practices[J].Klin Padiatr,2015,227(1):23-27.
[7]Ruiz-Pacheco JA,Vivanco-Cid H,Izaguirre-Hernández IY,et al.TREM-1 modulation during early stages of dengue virus infection[J].Immunol Lett,2014,158(1-2):183-188.
[8]Palmiere C,Bardy D,Mangin P,et al.Value of sTREM-1,procalcitonin and CRP as laboratory parameters for postmortem diagnosis of sepsis[J].J Infect,2013,67(6):545-555.[9]Qian L,Weng XW,Chen W,et al.TREM-1 as a potential therapeutic target in neonatal sepsis[J].Int J Clin Exp Med,2014,7(7):1650-1658.
[10]Dong J,Lin J,Wang B,et al.Inflammatory cytokine TSLP stimulates platelet secretion and potentiates platelet aggregation via a TSLPR-dependent PI3K/Akt signaling pathway[J].Cell Physiol Biochem,2015,35(1):160-174.[11]Rosse G.Quinalozinones as inhibitors of classⅠPI3K Kinases[J].ACS Med Chem Lett,2014,6(1):15-16.
[12]Jabbour E,Ottmann OG,Deininger M,et al.Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies[J].Haematologica,2014,99(1):17-18.
[13]Okkenhaug K.Signaling by the phosphoinositide 3-kinase family inimmunecells[J].AnnuRevImmunol,2013,31(10):675-704.
[14]Ghigo A,Damilano F,Braccini L.PI3K inhibition in inflammation:toward tailored therapies for specific diseases[J].Bioessays,2010,32(3):185-196.
[15]Foster JG,Blunt MD,Carter E,et al.Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies[J].Pharmacol Rev,2012,64(4):1027-1054.
[16]Yum HK,Arcaroli J,Kupfner J,et al.Involvement of phosphoinositide 3-kinases in neutrophil activation and the development of acute lung injury[J].J Immunol,2001,167(11):6601-6608.
[17]Martin EL,Souza DG,F(xiàn)agundes CT,et al.Phosphoinositide-3 kinase gamma activity contributes to sepsis and organ damage by altering neutrophil recruitment[J].Am J Respir Crit Care Med,2010,182(6):762-773.
[18]Prüfer S,Weber M,Sasca D,et al.Distinct signaling cascades of TREM-1,TLR and NLR in neutrophils and monocytic cells[J].J Innate Immun,2014,6(3):339-352.
[19]Cai M,Chen Q,Chen C,et al.Activation of triggering receptor expressed on myeloid cells-1 protects monocyte fromapoptosisthroughregulationofmyeloidcell leukemia-1[J].Anesthesiology,2013,118(5):1140-1149.
[20]Yeo JC,Wall AA,Luo L,et al.Rab31 and APPL2 enhance FcγR-mediated phagocytosis through PI3K/Akt signaling in macrophages[J].Mol Biol Cell,2015,11(7):1410-1457.
Role of the PI3K signaling pathway in sTREM-1 expression of RAW264.7 cells by LPS
FENG Qing-zhou1DU Juan1GAO Wei-liang2LIU Xuan1
1.Department of ICU,the Seventh People's Hospital of Shenzhen,Guangdong Province,Shenzhen518081,China;2.Department of Respiratory Medicine,the Second Clinical Medicial College of Ji′nan University,Guangdong Province,Shenzhen518081,China
Objective To investigate the role of the PI3K signaling pathway in sTREM-1 expression of RAW264.7 cells by LPS.Methods RAW264.7 cells of macrophage cell line were cultured,RAW264.7 cells were induced with the same concentration of LPS by different time,PI3K protein expression level was detected by Western blot,PI3K mRNA expression level was detected by the RT-PCR,the expression level of sTREM-1 was detected by enzyme linked immunosorbent assay method.The RAW264.7 cells were treated with LY294002 by different concentration,the changes of above indexes were observed.Results LPS could induce the PI3K and PI3K mRNA expression of RAW264.7 cells by dependent time.LY294002 could inhibit the PI3K and PI3K mRNA by dependent concentration.After PI3K signal transduction pathway was blocked by LY294002,the sTREM-1 expression was significantly inhibited by dose dependent.Conclusion The PI3K signaling pathway is induced in sTREM-1 expression of RAW264.7 cells by LPS.
Phosphoinositide 3-kinase;Lipopolysaccharide;Soluble triggering receptor expressed on myeloid cell-1
Q245
A
1674-4721(2015)05(b)-0011-04
2015-01-07本文編輯:衛(wèi)軻)
廣東省深圳市鹽田區(qū)科技計劃項目(201202 177)